Monitor for any subsequent licensing agreements, partnership expansions, or clinical trial initiations that could monetize the patent portfolio. Near-term stock movement is unlikely from patent publications alone.
Price Chart
Executive Summary
SciSparc announced that its majority-owned subsidiary NeuroThera, through its collaboration with Clearmind Medicine, has had three U.S. patent applications published covering novel combinations of LSD, ketamine, and ibogaine with NeuroThera's proprietary PEA technology for mental health, pain, and substance use disorders. This expands the intellectual property portfolio but is an early-stage, non-revenue event with no immediate financial impact.
Key Facts
- Three U.S. patent applications published covering combinations of LSD, ketamine, and ibogaine with palmitoylethanolamide (PEA).
- Applications cover potential therapeutic uses for depression, PTSD, pain, and substance use disorders.
- Patent applications build on prior IP covering MDMA + N-acylethanolamines for PTSD, anxiety, and eating disorders.
- NeuroThera is a majority-owned subsidiary of SciSparc; Clearmind Medicine (Nasdaq: CMND) is the collaboration partner.
- No financial terms, milestone payments, or revenue from the patents were disclosed.
Financial Impact
No financial figures disclosed; patent publications are procedural and do not generate immediate revenue.
Risk Factors
- Patent applications are not yet granted; issuance is uncertain and may be rejected or narrowed by the USPTO.
- No disclosed revenue or near-term commercialization path; the collaboration remains preclinical.
- SciSparc has no marketed products and relies on future development milestones; cash burn risk persists.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3367467 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.29 | awaiting T+5 | — | $1.29 (−0.04%) |
Oct 23, 2026 3d ago | 6-K | $1.09 | awaiting T+5 | — | $1.29 (+18.35%) |
Oct 22, 2026 4d ago | Press Release | $1.20 | awaiting T+5 | — | $1.29 (+7.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▲ +40.00% | ▲ +38.99% | $1.29 (+35.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 15, 2026 11d ago | Press Release | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 7, 2026 19d ago | 6-K | $4.64 $3.63 | ▼ −21.77% | ▼ −20.79% | $1.29 (−72.20%) |
Sep 30, 2026 26d ago | 6-K | $4.55 $4.43 | ▲ +2.64% | ▲ +3.94% | $1.29 (+71.65%) |
Sep 24, 2026 4w ago | 6-K | $5.39 $4.55 | ▼ −15.58% | ▼ −15.17% | $1.29 (−76.07%) |
Sep 23, 2026 4w ago | Press Release | $5.01 $4.72 | ▼ −5.79% | ▼ −5.11% | $1.29 (−74.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers